Clinical Trial Update: Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression [Phase 2]

View source ↗

Summary

Phase 2 long-term safety and tolerability study of BMS-820836 in treatment-resistant major depression was terminated; the update provides safety and tolerabilit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• BMS-820836

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Depression | Phase 2 | Status: TERMINATED